Trans-Pacific Technology Fund

Trans-Pacific Technology Fund (TPTF) is a technology-driven venture capital firm investing in innovative companies shaping the future of global business. TPTF focuses on disruptive, platform technologies across sectors such as advanced materials, health/life sciences, ICT, IoT, and robotics/automation. With a multi-stage investment strategy, TPTF supports companies from early to expansion/late stages, leveraging its extensive international resources and deep domain expertise to actively work with the leadership of its portfolio companies worldwide.

TPTF's investment approach emphasizes the belief that the cornerstone of every great company is great people. The firm considers itself a committed partner, providing capital and supporting entrepreneurs through its extensive international resources, deep domain expertise, and passion to build great companies. TPTF's global investment scope spans across Asia, North America, and Europe, seeking to invest in companies that are at the forefront of technological innovation.

The firm's portfolio includes companies such as Apexigen, a clinical-stage biopharmaceutical company developing antibody therapeutics for cancer treatment; Finch Therapeutics, a late clinical-stage company focused on therapeutics leveraging its Full-Spectrum Microbiota platform; and Quanergy Systems Inc., a provider of LiDAR sensors and perception software for real-time 3D data capture and processing. TPTF's diverse portfolio reflects its commitment to investing in companies that are driving technological advancements across various industries and regions.